BioWorld

June 29, 2004

Amgen's GDNF Misses In Phase II Parkinson's Trial

Amgen Inc.'s therapy for Parkinson's disease failed to meet its primary endpoint in a Phase II study. (BioWorld Today) Read More

Virogenomics New Spin-Off Artielle: $11M For MS Work

Alteon's Stock Sale Raises Up To $12.8M For Phase IIs

LSBC, University Of Louisville Join Up To Develop HPV Drugs

Other News To Note

Appointments And Advancements

Today's news in brief

BioWorld

BioWorld briefs for Dec. 11, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 11, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

US lawmakers demand that Kennedy be held accountable

BioWorld

As the systematic dismantling of the U.S. vaccine schedule escalates, the demands to hold Health and Human Services Secretary Robert Kennedy accountable are...

Medline plans record-setting $5.37B IPO

BioWorld MedTech

Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...